Skip to main content
Neurology

Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MD

The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]:

Source: Neurology Read More

Related Posts

Neurology <![CDATA[Nipocalimab Shows Sustained Disease Control and Symptom Improvement in 2-Year Extension Study]]>

<![CDATA[Nipocalimab Shows Sustained Disease Control and Symptom Improvement in 2-Year Extension Study]]>

April 28, 2026
Neurology <![CDATA[Key Takeaways on Neurorehabilitation Innovation at 2026 AAN: Nirmal Surya, MD, DM]]>

<![CDATA[Key Takeaways on Neurorehabilitation Innovation at 2026 AAN: Nirmal Surya, MD, DM]]>

April 28, 2026
Neurology <![CDATA[Neutrophil-to-Lymphocyte Ratio as a Scalable Signal in Dementia Risk Assessment]]>

<![CDATA[Neutrophil-to-Lymphocyte Ratio as a Scalable Signal in Dementia Risk Assessment]]>

April 28, 2026